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http://dx.doi.org/10.1016/j.ccell.2015.08.012SUMMARYThe associations of tricyclic antidepressants (TCAs) with reduced incidence of gliomas and elevated auto-
phagy in glioma cells motivated investigation in mouse models of gliomagenesis. First, we established
that imipramine, a TCA, increased autophagy and conveyedmodest therapeutic benefit in tumor-bearing an-
imals. Thenwe screened clinically approved agents suggested to affect autophagy for their ability to enhance
imipramine-induced autophagy-associated cell death. The anticoagulant ticlopidine, which inhibits the puri-
nergic receptor P2Y12, potentiated imipramine, elevating cAMP, a modulator of autophagy, reducing cell
viability in culture, and increasing survival in glioma-bearing mice. Efficacy of the combination was obviated
by knockdown of the autophagic regulatory gene ATG7, implicating cell-lethal autophagy. This seemingly
innocuous combination of TCAs and P2Y12 inhibitors may have applicability for treating glioma.INTRODUCTION
High-grade astrocytomas (anaplastic astrocytoma grade III [AA]
and glioblastoma [GBM]) have the highest incidence and mortal-
ity rate among primary brain cancer patients (Friedman et al.,
2000); survival benefits from current therapies are measured in
months. The identification of newmechanism-based therapeutic
targets and strategies that improve upon this bleak outlook is an
important agenda.
In recent years, the roles of catabolic recycling of cellular com-
ponents (autophagy) in malignant progression and in responses
to therapy have become a focus in glioma, and other cancers.
Although in some cases autophagy exhibits pro-tumorigenic ef-
fects (Hart et al., 2012), in gliomas autophagy has been sug-
gested to inhibit tumor progression and to potentiate responses
to conventional therapies (Aoki et al., 2008; Palumbo and Com-
incini, 2013). In the present study, we evaluated the mechanistic
effects and therapeutic potential of manipulating autophagy in
gliomas using repurposed USA Food and Drug Administration
(FDA)-approved agents.Significance
Glioma, a form of brain cancer, remains an intractable diseas
quate. Discovering new therapeutic strategies to combat gliom
to impair glioma growth and malignant progression by increas
approved drugs: tricyclic antidepressants (TCAs) and certain a
itor of the purinergic receptor P2Y12 promotes autophagy-asso
cAMP-signaling pathway. Pre-clinical trials in several models
peutic efficacy. Thus, combinations of TCAs and P2Y12 inhibito
to conventional glioma therapy.
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Imipramine Treatment Prolongs Survival
of Glioma-Bearing Animals
Long-term use of tricyclic antidepressants (TCAs) has been
associated with decreased incidence of gliomas (Walker et al.,
2011). Intrigued by this observation, we asked whether TCA
treatment might affect the progression of pre-existing low-grade
lesions to secondary GBMs in genetically engineered mouse
models of gliomagenesis. We and others have previously estab-
lished that p53 deficiency promotes the formation of high-grade
gliomas in animals expressing activated HRasV12 oncogene
(Marumoto et al., 2009; Shchors et al., 2013). For this study,
we generated two lines of mice, differing in their p53 status:
GFAP-HRasV12;GFAP-CRE;GFAP-LUC;p53flox/wt (referred to
here as GRLp53het mice) and GFAP-HRasV12;GFAP-CRE;
GFAP-LUC;p53flox/flox (GRLp53fko). The homozygous loss of
p53 in this context significantly accelerated the progression of
high-grade gliomas when compared with p53 heterozygous
animals (Figure S1A) (Shchors et al., 2013). These micee, for which standard-of-care treatments are largely inade-
as is therefore an important agenda. We describe a means
ing autophagic flux upon combining two classes of clinically
nticoagulants. We show that combining a TCA and an inhib-
ciated cell death in glioma cells via the EPAC branch of the
of glioma development and progression demonstrate thera-
rs could be considered for clinical evaluation as an adjuvant
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Figure 1. IM Treatment Improves Survival
and Decreases Malignancy in Engineered
Mouse Models of De Novo Gliomagenesis
(A) Kaplan-Meier survival analysis of tumor-
bearing GRLp53het animals in cohorts treated
with vehicle control (CTRL) or with IM (40 mg/kg/
day). Treatment was initiated 24 hr after tumor
detection (see Experimental Procedures). *p <
0.02 by the Mantel-Cox test.
(B) The distribution of grade II, III, and IV tumors in
end-stage GRLp53het mice, control (CTRL) and
treated with IM. The histopathological score was
determined as described in the Supplemental In-
formation. Statistical analysis was performed us-
ing the chi-square test.
(C) Representative images of an IHC analysis of
cell proliferation in GRLp53het tumors, control
(CTRL) and treated with IM, assayed for Ki67 (see
Supplemental Information). The scale bars repre-
sent 200 mm; insets are magnified 143. **p < 0.001
by unpaired Student’s t test.
(E) Survival of tumor-bearing GRLp53fko animals
in a control group (CTRL) or one treated with IM.
Treatment began 24 hr after tumor detection (as in
A). The size of each cohort is indicated. No sta-
tistically significant difference was detected by the
Mantel-Cox test.
(F) RT-qPCR analysis of mRNA expression of the
p53 target genes: CDKN1a (p21cip1), puma, and
gadd45a in tumor-derived primary cultures from
GRLp53het and GRLp53fko animals following
24 hr of exposure to IM in vitro. Data are presented
as fold induction relative to control vehicle-treated
samples. Ns, no statistical significance by two-
way ANOVA. Three independently derived tumor
cultures were analyzed, each in triplicate.
(G) Representative images from an IHC analysis of
apoptosis assayed by activated caspase-3 (CC-3)
staining in brains collected from GRLp53het and
GRLp53fko mice, control or treated with IM for
72 hr (see Supplemental Information). The scale
bars represent 50 mm. Quantification of CC3-
positive cells in tumor fields is presented to the
right. Statistical analysis was performed using a
two-tailed Student’s t test.
See also Figure S1.reproducibly develop high-grade astrocytomas (AA and
GBM-like lesions) (Figure S1). The tumors developing in the
GRLp53het and GRLp53fko animals varied in histopathological
grade, with the GRLp53fko model having a higher incidence of
the GBM-like tumors (80% versus 59% in theGRLp53hetmodel)
(Figure S1B). The molecular alterations detected in GBMs from
the GFAP-HRasV12-driven model of gliomagenesis are similar
to those observed in a range of high-grade human gliomas,
including overexpression of EGF receptor and increased activity
of the AKT/mTOR signaling pathway (Shannon et al., 2005) (Fig-
ure S1C). The incorporation of a luciferase reporter enables non-
invasive monitoring of disease progression (Figures S1G–S1J
and Supplemental Information).
We first assessed the impact on tumor-bearing GRLp53het
animals of a TCA, imipramine (IM). Asymptomatic GRLp53het
animals with similarly sized incipient gliomas were stratified
into control and IM-treated cohorts. The IM cohort (5 days/week)Cwas treated until a defined endpoint 13 weeks later or until the
effects of tumor progression dictated euthanasia. The IM treat-
ment prolonged the overall survival of treated animals, with ame-
dian survival of 31 days compared with 13 days in the control
cohort (Figure 1A). The IM-treated tumors exhibited a lower his-
topathological grade and had a reduced proliferative index, as
assessed by Ki67, compared with the control group; only 36%
of treated mice had progressed to high-grade GBM-like lesions,
versus 75% in the control cohort (Figures 1B–1D). In contrast,
when GRLp53fko mice (which exhibit accelerated tumor pro-
gression) (Figure S1A) were similarly selected and treated with
IM, there was no survival advantage (Figure 1E). Thus, IM treat-
ment was able to delay the progression of incipient low-grade
gliomas but not the more aggressive disease. The differential
sensitivity ofGRLp53het andGRLp53fko lesions to IM treatment
was independent of transcriptional activation of p53 targets
(Figure 1F).ancer Cell 28, 456–471, October 12, 2015 ª2015 Elsevier Inc. 457
To understand the basis for the therapeutic efficacy of IM
against low-grade gliomas, we examined the effects of IM action
in tumors as well as cultured glioma cells of mouse and human
origin. It has been suggested, depending on the context, that
TCAs disrupt tumor cell homeostasis via several mechanisms,
including accentuated autophagy, alterations in lysosomal turn-
over, and elevated apoptosis (Jahchan et al., 2013; Jeon et al.,
2011; Petersen et al., 2013). Analysis of tumor samples collected
fromGRLp53het andGRLp53fko control and IM-treated animals
did not reveal a heightened frequency of apoptosis in the gliomas
treated with IM (Figure 1G). Therefore, we focused on the impli-
cation that IM could bemodulating autophagy (Jeon et al., 2011).
The process of autophagy involves multiple stages. Following
initiation, evidenced by autophagosome formation, the process
can either become stalled at a midpoint (non-functional) or be
productive (functional) at completing the degradation of envel-
oped cellular organelles, termed autophagic flux. A common
metric for the initiation of autophagy involves the microtubule-
associated protein light chain 3 (MAP1 LC3, hereafter referred
to as LC3). The conversion of cytosolic LC3I into phosphatidyl-
ethanolamine-conjugated LC3II closely correlates with the num-
ber of autophagosomes in the cell and is manifested as puncta
by immunohistochemical (IHC) analysis or as a faster migrating
LC3 isoform in SDS-PAGE (Mizushima et al., 2010). Tumor sam-
ples were collected from symptomatic tumor-bearingGRLp53ko
animals, subjected to IM or control-vehicle treatment for
72 hours, and analyzed for LC3 expression. We detected an in-
crease in the abundance of LC3-II puncta per cell in tumors
collected from the IM-treated animals compared with control tu-
mors (mean ± SEM 3.174 ± 0.56 and 1.088 ± 0.35, respectively),
as well as an increase in the LC3II isoform visualized by SDS-
PAGE in tumor lysates and primary glioma cells derived from
the GRLp53fko and GRLp53het mice and in human GBM cell
lines (Figures 2A–2D). This effect was not associated with altered
transcriptional regulation of LC3 (Figure 2E).
During the final stages of the autophagic process, the LC3-II
protein is degraded in autolysosomes. Pharmacological inhibi-
tion of LC3-II degradation in lysosomes is used as a metric of
productive autophagic flux (Mizushima et al., 2010). Indeed, an
inhibitor of lysosomal acidification, Bafilomycin A1 (Baf1), was
found to promote LC3 accumulation in IM-treated glioma cells
(Figure 2F), indicating that it was otherwise being degraded in
the end stage of autophagy.
A Cell-Based Screen for Drugs that Enhances IM’s
Effects on Autophagy and Cell Survival
IM exposure interfered with the progression of low-grade incip-
ient neoplasia in GRLp53het mice but was ineffective in
GRLp53fkomice exhibiting more rapid disease progression (Fig-
ures 1A and 1E). Similarly, in a cohort of human glioma patients,
in which high-grade glioma patients were overrepresented, post-
diagnostic treatment with TCAs produced very limited survival
benefits (Walker et al., 2012). We reasoned that IM’s modest ac-
tivity in high-grade gliomas could be potentially enhanced in
terms of therapeutic benefit by a combinatorial approach. Given
that we (Figure 2) and others (Jeon et al., 2011) observed that IM
modulates autophagic flux in this cell type, we screened for
agents that could intensify IM-mediated regulation of autophagy
and enhance its anti-tumoral activity in glial cells. Notably, other458 Cancer Cell 28, 456–471, October 12, 2015 ª2015 Elsevier Inc.clinically approved drugs have recently been revealed to modu-
late autophagy by affecting different stages or regulators of this
process (Hundeshagen et al., 2011; Williams et al., 2008). We
evaluated a set of agents that were implicated to modulate auto-
phagy at distinctive nodes (Figure 3A), focusing on drugs that
were not associated with significant side effects in humans
(Table S1).
We tested the effects of the selected drugs, alone and in com-
bination with 20 or 40 mM IM, on cell survival in a panel of six hu-
man glioma cells lines differing in PTEN, p53, and INK4ARF
status. Proliferation and survival were measured 72 hours
following exposure (Figure S2A). The maximum tested dose of
each drug was based upon its highest non-toxic concentration
in plasma of human patients. Only one of the tested agents,
the anti-platelet drug ticlopidine (TIC), synergized with IM in
reducing cell survival in all tested lines (independent of the activ-
ity of the AKT/mTOR signaling pathway and of EGF receptor
levels) (Figure S2B). The combination was also effective in pri-
mary GBMcultures derived from theGRLp53het andGRLp53fko
mice and had minimal toxicity toward normal mouse astrocytes
in vitro (Figures 3B, S2A, S2C, and S3A).
TIC inhibits the ADP receptor P2Y12, thereby abolishing the
ADP-induced downregulation of adenylyl cyclase. In normal tis-
sue, expression of P2Y12 is limited to platelets and glial cells. In
gliomas, P2Y12 is expressed at higher levels in cancer cells than
in normal astrocytes (Baranska et al., 2004; Carrasquero et al.,
2005) (Figure S3B). Concordantly, P2Y12 was elevated in
GRLp53het gliomas cells compared with wild-type astrocytes
and was detected in all tested human glioma cell lines
(Figure S3C).
We hypothesized that inhibition of P2Y12 activity in conjunc-
tion with TCA treatment was increasing the cellular level of
cAMP by upregulating adenylate cyclase (Hollopeter et al.,
2001; Toki et al., 1999), which in turn elevates the rate of auto-
phagic flux (Ugland et al., 2011) (Figure 3C). If indeed IM and
TIC act by targeting Ga and P2Y12 respectively, then other
chemically distinct drugs targeting these proteins should have
similar combinatorial effects in gliomas. Therefore, we analyzed
two additional TCAs, desipramine (DMI) and trifluoperazine
(TFP), and two additional P2Y12 inhibitors, prasugrel (PGL) and
clopidogrel (CDL), alone and in combination, for their ability to
reduce survival of glioma cells. All of the analogous combina-
tions of a TCA and a P2Y12 inhibitor synergistically reduced the
survival of glioma cells to varying degrees, strengthening the
conclusion that IM+TIC treatment was elevating cAMP (Fig-
ure 3D). Among the agents tested, DMI was more potent in
inducing cell death in vitro compared with IM, and the P2Y12 in-
hibitor CDL was similarly efficacious to TIC (Figure 3D). Beyond
the immediate result of target validation, DMI and CDL warrant
future evaluation as therapeutic agents.
Having established that drug combinations targeting the auto-
phagic regulatory circuitry reduced cell survival (Figures 3B, 3D,
and 3E), we next sought to characterize the mechanism of cell
death. With regard to apoptosis, we found that the reduced sur-
vival of LN71 glioma cells treated with IM+TIC was not associ-
ated with the cleavage of the caspase-3 target protein poly
ADP ribose polymerase (PARP), suggesting that IM+TIC treat-
ment induces non-apoptotic cell death in LN71 cultured glioma
cells (Figure 3F). Congruent with this observation, the
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Figure 2. IM Treatment Induces Autophagy in Human and Mouse Glioma Cells
(A) Representative IHC analysis of LC3 expression and distribution in tumors collected from control (CTRL) and animals treated with IM for three days (see
Supplemental Information). The scale bars represent 50 mm. Insets are magnified 83.
(B) Quantification of LC3II puncta/cell in tumors described above. Statistical analysis was done by unpaired Student’s t test.
(C) Immunoblotting analysis of LC3 expression inGRLp53het andGRLp53fko tumors collected from control and IM-treated animals treated as described above.
Quantification of LC3 levels in treated animals relative to the respective controls is presented below the immunoblot.
(D) Immunoblotting analysis of LC3 expression inmouse and human glioma cells, either control (sham-treated) (-) or IM treated (+) for 24 hr. Independently derived
primary cell lines from the GRLp53het (H454, A923) and GRLp53fko (D798, 9312) animals and human GBM cell lines (LN229, LN71, LN 443) were treated.
(legend continued on next page)
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pan-caspase inhibitor Z-VAD-(0Me)-fmk failed to protect glioma
cells from the IM+TIC-induced cell death (Figures 3G and 3H). In
some experimental systems, IM has been implicated as an inhib-
itor of autophagy that acts by increasing lysosome membrane
permeability, thereby causing an increase in apoptosis (Ashoor
et al., 2013; Petersen et al., 2013). The lack of detectable
apoptosis and the elevated autophagic flux (further described
below) seen in the IM-treated glioma cells suggest that the re-
ported ability of IM to inhibit rather than accentuate autophagy
is not operative in this particular cancer cell type. In addition,
the inhibition of necroptosis (programmed cell death by necrosis)
by necrostatin-1 (25 mM), a small-molecular inhibitor of necrop-
tosis (Degterev et al., 2005), did not block IM+TIC-induced cell
death (Figures 3I and 3J).
Having excluded apoptosis and necroptosis asmajor determi-
nants of the induced cell death, we proceeded to evaluate the
role of heightened rates of autophagy in reducing survival of
cultured glioma cells. A number of studies suggest that in-
creases in cellular autophagy in vitro and in vivo can promote
non-apoptotic cell death (for reviews, see Jain et al., 2013; Tsu-
jimoto, 2012). To determine whether IM+TIC was also modu-
lating the rate of cellular autophagy, as observed for IM
treatment (Figure 2A), we first analyzed expression of LC3-II
in LN71 glioma cells mock-treated or treated with IM, TIC, or
IM+TIC. Indeed, IM+TIC treatment further enhanced LC3-II
levels compared with IM or TIC (Figure 4A).
Autophagy is a dynamic, multi-stage process. The elevated
levels of LC3-II reflect the initiation of the autophagic process
but not necessarily its completion; as such, elevated LC3-II
can be indicative of an increase in autophagy or, alternatively,
stalling midcourse. To distinguish between these possibilities,
we performed immunoblotting analysis of the cellular levels of
p62/SQSTM1, which is known to recognize damaged proteins
and shepherd them in autolysosomes, where p62 is concomi-
tantly degraded. As such, cellular levels of p62/SQSTM1 reflect
the status of autophagic flux in the cell (Bjørkøy et al., 2009; Pan-
kiv et al., 2007). The levels of p62/SQSTM1 in LN71 glioma cells
treated with IM+TIC were found to be significantly reduced
compared with control, indicative of increased rates of functional
autophagy (Figure 4A). Both Baf1 and the lysosomotropic re-
agent chloroquine (CQ) inhibited degradation of LC3-II in
IM+TIC-treated samples (Figures 4B and 4C). The observed
changes in the MAP1LC3 and p62/SQSTM1 protein levels in
response to IM, TIC, and IM+TIC treatments were not a result
of transcriptional regulation (Figure S3D), consistent with a direct
effect on the autophagic machinery. Moreover, CQ treatment
partially impedes IM+TIC-induced cell death (Figure S3F), further
indicating that IM+TIC accentuates autophagy.
To further evaluate the outcome of IM+TIC treatment on gli-
oma cells, we used a mRFP-EGFP-LC3 tandem-tagged fluores-
cent protein (ptf-LC3) (Kimura et al., 2007). EGFP is sensitive to
lysosomal proteolysis, while red fluorescent protein (mRFP) re-
tains fluorescence in autolysosomes. Therefore, ptfLC3 allows(E) RT-qPCR analysis of LC3 (MAP1LC3) mRNA expression in GRLp53fko tumors
no statistical significance by unpaired Student’s t test.
(F) Representative immunoblotting of LC3 proteins in primary glioma cell cultures
or in conjunction with 50 nM Baf A for 4 hr (see Supplemental Information). Quanti
the immunoblot.
460 Cancer Cell 28, 456–471, October 12, 2015 ª2015 Elsevier Inc.one to measure both induction of autophagy (mRFP+EGFP pos-
itive puncta) and productive autophagic flux reflected in an in-
crease in the percentage of mRFP-only positive vehicles. A
48 hr IM+TIC treatment of LN71 glioma cells transfected with
ptfLC3 resulted in an increase in red-only fluorescent vesicles
compared with mRFP+EGFP+ puncta (Figure 4D), indicative of
EGFP proteolysis in lysosomes, consistent with the other data
indicating that the combination IM+TIC is promoting functional
autophagy in glioma cells.
To substantiate this conclusion, we interfered with the expres-
sion of two key autophagic regulatory genes, Beclin-1 and ATG-
7. Small hairpin RNA (shRNA)-mediated downregulation of
Beclin-1 resulted in statistically significant protection from
IM+TIC-mediated death in LN71 glioma cells (Figures 4E, S3G,
and S3H). Congruently, downregulation of ATG-7 in LN71 cells
also interfered with the IM+TIC-induced death (Figures 4E, 4G,
and S3G–S3I). Moreover, shRNA-mediated downregulation of
both Beclin-1 and ATG-7 impeded the IM+TIC-mediated induc-
tion of p62/SQSTM1 degradation (Figure 4F). These results
strengthen the conclusion that the cell death elicited by IM+TIC
is a consequence of elevated (and not reduced) rates of
autophagy.
To further characterize the status of autophagic flux in IM+TIC-
treated cells, we performed transmission electron microscopy
analysis (EM) of glioma cell lines LN71 and LN229 treated with
vehicle control or IM+TIC for 6 or 18 hours. We observed an in-
crease in cellular lysosomes as well as autophagic vacuoles
(AVs) following 6-hour exposure to IM+TIC. Prolonged exposure
to IM+TIC did not result in additional accumulation of lysosomes,
although LN71 exhibited a slight reduction in total lysosomal
number; there was, however, a statistically significant increase
in both early (or initial) AVs and late (degradative) AVs (AVd) (Fig-
ure 4H). Occasionally, IM+TIC treatment caused the formation of
‘‘empty’’ autophagosomes, presumably with fully digested con-
tents (Figure 4H, red arrows). Taken together, our data suggest
that IM+TIC treatment causes non-apoptotic cell death and ac-
centuates autophagic flux in human glioma cell lines in vitro.
Co-treatmentwith IM and TIC Induces Autophagy In Vivo
Having established that combinatorial treatment of LN71 human
glioma cells in vitro results in induction of autophagy and non-
apoptotic cell death, we proceeded to investigate the outcome
of IM+TIC treatment on cell autophagy in vivo. IM+TIC treatment
ofmice bearing incipient gliomas produced a significant increase
in LC3-positive puncta in tumor cells compared with control-
treated tumors (Figure 5A); this increase was not associated
with altered expression of theMAP1LC3 gene (data not shown).
We further visualized lysosomes with anti-LAMP1 (lysosomal
associated membrane protein 1) antibodies and observed an
evident co-localization with LC3 dots (Figure 5B). Therefore, au-
tolysosome formation is increased in IM+TIC-treated tumors
compared with control tumors, indicative of productive autopha-
gic flux., sham-treated or treated with IM for 72 hr (see Supplemental Information). Ns,
collected fromGRLp53het andGRLp53fko animals, control or IM treated alone
fication of LC3II levels in treated cultures relative to controls is presented below
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Figure 3. TIC Synergizes with IM in Promoting Death in Cultured Mouse and Human Glioma Cells
(A) Schematic representation of the proposed regulation of cell autophagy by different clinically approved drugs. The agents usedwere either identified using cell-
based screens (Hundeshagen et al., 2011; Williams et al., 2008) or were previously established to be modulators of autophagy (for references, see Table S1). Six
drugs (highlighted in pink font) targeting different nodes in this circuit were tested, alone and in combination with IM (see Figure S2).
(legend continued on next page)
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To further investigate the effects of increased autophagic flux
in the IM+TIC-treated tumors, we performed a morphological
analysis by EM. We found that 9.5 ± 4.6% of the IM+TIC-treated
glioma cells in vivo exhibited features of autophagy-associated
cell death (AACD) (as defined by (Tasdemir et al., 2009; Petrini
et al., 2012; Tinari et al., 2008) (Figure 5C). Namely, the dying
cancer cells contained intact nuclei and had increased vacuoli-
zation, reduced numbers of cellular organelles, and increases
in the number and size of AVs (Figure 5D) and in the size of
AVd (Figure S4A).
We next sought to functionally connect autophagy with the ef-
fects of IM+TIC treatment on gliomas in vivo. LN229 glioma cells
were engineered with an ATG7 shRNA lentiviral vector to have
reduced expression of ATG7 (described in Supplemental Infor-
mation). As presented in Figures 5E and 5F and Figure S4B,
the ATG7 knockdown obviated the tumor growth inhibition and
survival benefit elicited by IM+TIC, indicating that the autophagic
regulatory circuit was important for the therapeutic effects of
these agents.
The Combination of IM and TIC Has Therapeutic Benefit
in Multiple Models of Glioma In Vivo
To further assess the therapeutic potential of IM+TIC in gliomas,
we evaluated the efficacy of the combination in mice bearing de
novo tumors. GRLp53het and GRLp53fkomice with asymptom-
atic incipient neoplasias were identified as described earlier,
stratified into cohorts, and subjected to IM, TIC, or IM+TIC treat-
ment (5 days/week) until a defined endpoint 13 weeks later, or
until tumor progression dictated cessation. The IM+TIC treat-
ment resulted in a significant survival advantage over either
mono-therapy for both GRLp53het (59% GBM-like and 29%
AA at end stage) and GRLp53fko (80% GBM-like at end stage)
animals, without appreciable toxicity (Figures 5G and 5H).
Greater than 50% of the GRLp53het animals survived more
than 90 days following the identification of lesions, compared
with 13 days in the control group (Figure 5G). The end-stage tu-
mors in the IM+TIC-treated cohort had lower grade malignancy(B) Survival of glioma cells subjected for 3 days to vehicle control, 40 mM IM, or inc
drug combination that induced cell death in all tested glioma cells. The experimen
IM and TIC were tested (Figure 3D).
(C) A blowup from (A) highlighting the proposed mechanism of action of P2Y12 inh
autophagy.
(D) Effects of three TCAs, alone or in combination with three P2Y12 inhibitors, on th
inhibitors were TIC, PGL, and CDL. The concentration of each agent is shown. Th
with vehicle control for each drug and drug combination. Significant effects of th
(E) Analysis of lactate dehydrogenase (LDH) release in supernatants of LN71 cell
Results are presented as the fold increase in LDH relative to control-vehicle-treat
experiment was conducted in triplicate. *p% 0.01 and **p% 0.005 by two-tailed
(F) Representative immunoblot for cleaved PARP as ameasure of apoptosis in LN
IM+TIC. Taxol (100 nM for 24 hr) served as a positive control for induction of apo
(G) Survival of LN71 cells treated for 48 hr with vehicle control, 40 mM IM alone, or I
apoptosis-inducing agent Taxol was used to illustrate zVad(Ome)-fmk activity. T
**p% 0.005. ns, no statistically significant difference by a two-tailed Student’s t
(H) LDH release into supernatants of LN71 cells treated as in (G). *p% 0.05 and *
t test.
(I) Survival of LN71 cells subjected treated for 24 hr with vehicle control, 40 mM
(25 mM). The necrosis-inducing agent shikonin (Huang et al., 2013) was used to
Supplemental Information. Ns, no statistically significant difference. *p = 0.02 an
(J) LDH release into supernatants of LN71 cells treated as in (I). **p% 0.01. ns, n
See also Figure S2 and Table S1.
462 Cancer Cell 28, 456–471, October 12, 2015 ª2015 Elsevier Inc.compared with both control cohorts and animals subjected to
IM and TIC mono-therapy. The treatment also extended the me-
dian survival of GRLp53fko late-stage tumor-bearing animals,
from 14–36 days in the IM+TIC-treated group (Figure 5H). The
IM+TIC-treated GRLp53fko mice also had a higher percentage
of lower grade (II and III) tumors compared with both the control
group and animals treated with IM or TIC mono-therapy (Fig-
ure 5H). We further substantiated the therapeutic potential of
IM+TIC treatment in vivo in an alternative model of gliomagene-
sis, GNLp53fko, elicited by the targeted deletion of the NF1 tu-
mor suppressor gene that is implicated in a subclass of human
glioma (Supplemental Information and Figures S4C and S4D).
In this model, the survival of late-stage tumor-bearing mice
treated with IM+TIC was 23.8 ± 3.7 days, compared with 5 ±
1.1 days in the control group (Figure S4E).
IM+TIC treatment was also beneficial when applied during
the terminal stage of disease progression, when animals were
exhibiting signs of neurological distress due to tumor burden.
The mean survival of the IM+TIC treated animals was improved
compared with the control group from 2.4–5.7 days while either
IM or TIC mono-therapy was inefficacious (Figure 5I). The
IM+TIC-treated tumors exhibited the reduction of cancer cell
proliferation (Figure 5J). Thus, autophagy-promoting IM+TIC
therapy is capable of slowing the rapid progression of late-
stage disease. In notable contrast, inhibition of autophagy by
CQ did not impart any survival advantage during analogous
end-stage therapeutic trials (Figure S4F), further supporting
the consensus of the data that IM+TIC is elevating autophagy
to a cell-lethal level.
We further generated a syngeneic transplantable mouse
model of glioma (Supplemental Information and Figures S4G
and S4H), involving orthotopic inoculation of 5 3 105 of primary
glioma cells derived from an end-stage GRLp53het mouse.
Three days after transplantation, recipient animals were stratified
into groups and mock-treated or treated with IM, TIC, or IM+TIC
5 days a week for 10 weeks or until the tumor burden required
euthanasia. The animals treated with IM+TIC exhibitedreasing doses of TIC, alone or in combination with IM. Red arrows highlight the
t was conducted as described in the Supplemental Information. Lower doses of
ibitors in combination with TCAs, which collectively accentuate the level of cell
e survival of LN71 glioma cells. The TCAswere IM, DMI, and TFP, and the P2Y12
e survival of treated cells is indicated as a percentage of the viable cells treated
e treatments on cell survival are denoted in red font.
s treated with IM and TIC in the indicated doses for the duration of three days.
ed cells. Triton X-100 (0.1%) was used as a positive control for the assay. The
Student’s t test.
71 cells, either control-treated or treated for 24 hr with 40 mM IM, 100 mMTIC, or
ptosis. Beta-actin was used as a loading control.
M+TIC, with or without the pan-caspase inhibitor z-Vad(OMe)-fmk (50 mM). The
he experiment was conducted as described in the Supplemental Information.
test.
*p% 0.005. ns, no statistically significant difference by a two-tailed Student’s
IM alone, or IM+TIC, with or without the RIPK1 inhibitor necrostatin-1 (Nec-1)
document Nec-1 activity. The experiment was conducted as described in the
d ***p < 0.005, analyzed by a two-tailed Student’s t test.
o statistically significant difference by a two-tailed Student’s t test.
A B
C D
E
F
H
G
(legend on next page)
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prolonged overall survival compared with the control cohort
(Figure S4I).
As described above, the IM+TIC combination also reduced
the growth of subcutaneous (s.c.) transplanted LN229 glial tu-
mors (Figures 5E and 5F). To substantiate this result in the
context of the CNS microenvironment, we established an ortho-
topic transplant model of human GBM (described in Experi-
mental Procedures). Four days after transplantation with
LN229 cells, the animals were stratified into cohorts and treated
as described above. IM+TIC treatment extended survival of the
tumor-bearing animals from 51 days’ median survival in the con-
trol group to 61 days in the treated cohort (Figure S4J). In
contrast, IM and TIC as single agents had no demonstrable ef-
fect in prolonging the survival of animals bearing aggressive
transplanted tumors of mouse or human origin (Figures S4K
and S4L). IM+TIC also elicited changes in tumor histopathology.
The treated tumors contained large areas of tissue necrosis and
displayed reduced cellularity compared with control tumors
(Figure S4M).
IM and TIC Coordinately Upregulate cAMP Levels
in Gliomas
A number of studies implicate cAMP in the induction of auto-
phagy (Mestre and Colombo, 2012; Ugland et al., 2011) (Fig-
ure 3A). TCAs and P2Y12 inhibitors are suggested to upregulate
cAMP levels in the cell by distinct mechanisms (Defreyn et al.,
1991; Donati and Rasenick, 2005). To determine whether the
observed synergistic effects of the IM+TIC treatment on survival
and histopathology are mediated by modulation of cAMP levels
in gliomas, we analyzed cAMP concentrations in GRLp53fko tu-
mors untreated or treated with each agent alone or in combina-
tion. The 3-day treatment of animals with IM and TIC as mono-
therapy did not affect cAMP levels in tumors, whereas IM+TIC
increased cAMP levels in the tumor tissue (Figure 6A). Similarly,
although neither agent alone affected cAMP levels in glioma cellFigure 4. The Combination of IM+TIC Increases Autophagic Flux In Vit
(A) Representative immunoblot for p62 and LC3 protein expression in LN71 ce
Supplemental Information). *p < 0.05 and **p < 0.02 by unpaired Student’s t test
(B) Representative immunoblotting of p62 and LC3 proteins in LN71 cell cultures,
(Baf A), for 4 hr (see Supplemental Information). Quantification of levels in treated
(p62) the immunoblot.
(C) Representative immunoblot of LC3 proteins in LN71 cells, control or treated fo
after IM+TIC. #Non-specific band. *p < 0.04 by unpaired Student’s t test.
(D) Analysis of autophagosomes (EFGP+ and mRFP+) and autolysosomes (mRFP
LN71 cells, control or treated for 48 hr with 40 mM IM + 50 mMTIC. On the right, qua
(E) Survival of LN71 glioma treated for 2 days with 40 mM IM, 50 mM TIC, or IM+TI
determined by trypan blue exclusion method. ***p% 0.001 determined by two-w
(F) Representative immunoblotting analysis for p62 protein expression in LN71 c
CTRL shRNA (LO.1) treated for 24 hr with IM+TIC or sham control (see Supplemen
value of 1.
(G) Analysis of LDH release in supernatants of LN71 transfected with control shRN
or IM+TIC for 3 days. The results are presented as the fold increase in LDH relativ
*p% 0.05 by a two-tailed Student’s t test.
(H) Representative EM images of LN71 and LN229 cells, control or treated for 6 o
images represented in the magnified insets. Cellular organelles were identified as
late or degradative AVs (blue arrows); Ly, lysosomes; N, nucleus; Px, peroxisomes
point to ‘‘empty’’ autophagolysosomes. Analysis was performed according to p
fication of cellular Ly, AV, and Px in LN71 and LN229 cells, control or IM+TIC trea
way ANOVA. The analysis was performed in triplicate. At least 14 independent im
See also Figure S3.
464 Cancer Cell 28, 456–471, October 12, 2015 ª2015 Elsevier Inc.lines, IM+TIC treatment increased cAMP levels when adjusted to
total protein concentration (Figure 6B).
The cAMP signaling circuit involves a number of downstream
effectors, including PKA and CREB, and the recently described
EPAC-1/2 (for review, see Gloerich and Bos, 2010) (Figure 6C).
Both branches of the cAMP circuit are known to regulate the
ERK-signaling pathway (Ster et al., 2007; Vossler et al., 1997),
activation of which can in turn lead to an increase in autophagic
flux (Ugland et al., 2011). A number of cAMP analogs with
different specificities for these effectors have been characterized
(Christensen et al., 2003) (Figure 6C). To determine if the acti-
vated cAMP signaling circuitry is involved in the reduced survival
of IM- and IM+TIC-treated glioma cells, we first tested a cAMP
analog, Dibutyryl-cAMP (dbcAMP), which has high specificity
for PKA (Christensen et al., 2003), alone and in combination
with IM or TIC in LN71 cells. The co-treatment of cells with IM
or TIC in the context of ectopically increased levels of dbcAMP
had no impact on glioma cell survival (Figure 6D). Congruent
with this observation, the PKA-specific inhibitor KT5720 had little
effect on IM+TIC-mediated death in vitro. We also did not
observe increased phosphorylation levels of PKA targets in
response to IM+TIC (Figure S5).
In contrast, perturbation of the EPAC branch had a discernible
effect. A non-hydrolyzable cAMP analog, 8-CPT-cAMP, which
selectively activates EPAC, and a highly specific EPAC agonist,
8-CPT-Me-cAMP-AC (Vliem et al., 2008), both intensified the IM-
and TIC-mediated cell death in glioma cells (Figures 6E and 6F).
Conversely, shRNA-mediated downregulation of EPAC1 levels
using two different shRNAs partially blocked the IM+TIC-
induced cell death in gliomas (Figures 6G–6J). In light of these re-
sults, we conclude that elevating cAMP levels by combining
TCAs and inhibitors of purinergic receptor P2RY12 (Figure 7) is
retarding gliomagenesis. Consequently, we establish the impor-
tance of this pathway in malignant brain tumor progression as
suggested by epidemiological analysis in the case of TCAsro
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(Walker et al., 2011) and association with elevated expression for
P2RY12 (Figure S6).
DISCUSSION
In this study, we assessed the hypothesis that perturbation of
autophagy could have a deleterious effect on glioma progres-
sion, motivated both by an epidemiological study suggesting
that chronically depressed patients being treated long term
with TCAs had a reduced incidence of glioma (Walker et al.,
2011) and by experimental evidence that one such agent, IM,
modulated autophagy of glioma cells in culture (Jeon et al.,
2011). Because IM mono-therapy only modestly prolongs the
survival of tumor-bearing animals, we hypothesized that
combining IM with other agents known to potentiate autophagy
at distinctive nodes in the autophagic regulatory circuit might in-
crease its therapeutic benefit. Among six such drugs tested in a
screen of human GBM cell lines, only TIC, an antiplatelet agent
targeting the purinergic receptor P2Y12 (P2RY12), exhibited a
synergistic effect with IM in impairing cell survival.
Although P2RY12 is not reported to be highly expressed in
normal tissues other than platelets and glia (Hollopeter et al.,
2001), it is upregulated in different types of human tumors and
appears to be associated with poor prognosis for patients with
glioma, colon, and non-small-cell lung cancer (NSCLC) (Fig-
ure S6). Unconventional roles for purinergic receptors in cancer
progression are beginning to be explored (Di Virgilio, 2012). Here
we present evidence that P2RY12 inhibitors, although ineffica-
cious as mono-therapy in glioma, can synergize with three
different TCAs, markedly elevating cell death. Although treat-Figure 5. Combined Treatment with IM+TIC Elevates Autophagy and P
(A) Representative IHC analysis of LC-3 expression in tumors collected from tum
day) + TIC (1 mg/kg/day) daily for 72 hr (see Supplemental Information). The scale
per cell). Data are presented as mean ± SEM. Statistical analysis was performed
(B) Intracellular localization of LC-3 and the lysosomal marker LAMP1 in tumors, e
by confocal microscopy (see Supplemental Information). The graph presents LC3
ns, no statistical significance by a two-tailed Student’s t test.
(C) Representative EM images ofGRLp53fko tumors treated either with vehicle co
and experimental details, see Supplemental Information. The scale bars represe
acterized by cell shrinkage, extensive vacuolization, and depletion of organelles.
AACD, presented as percentage of cells showing this features in ultrathin sections
(D) Exemplary images of organelles identified in GRLp53fko tumors. AVd (L), late
(Note the typical double membrane [red arrows] characterizing AVi.) To the right is
for 48 hr with IM+TIC, per 100 mm2 cytoplasm. At least 20 cell bodies with clearly v
**p < 0.005 and ***p < 0.0001 by a two-tailed Student’s t test.
(E) Effects of vehicle control or IM+TIC treatment on tumor volumes (left column) o
control (shCTRL) or shATG7. Tumor volumes were determined at a defined en
determined when the average tumor volume of each cohort reached end stage, a
two-tailed Student’s t test.
(F) Therapeutic potential of IM+TIC treatment presented as the reduction in the
calculated when tumors from vehicle-treated mice reached an average size of 8
(G) Survival of tumor-bearing GRLp53het animals subjected to the indicated
n = cohort size. ***p < 0.0001, **p < 0.005, and *p % 0.02 by the Mantel-Cox t
GRLp53het animals; see the Supplemental Information for grading metrics.
(H) Survival of tumor-bearingGRLp53fko animals subjected to the indicated treatm
and **p% 0.005 by the Mantel-Cox test. n = number of animals per cohort. The d
(I) Scatterplot shows the survival of symptomatic (end-stage) tumor-bearing an
n = cohort size. ***p < 0.001. ns, no statistical significance by a two-tailed Stude
(J) IHC analysis of cell proliferation assayed by Ki67 expression (shown) and BrdU
(see Supplemental Information for methods). The scale bars represent 50 mm. Q
significance by a two-tailed Student’s t test.
See also Figure S4.
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TIC, respectively) exhibits therapeutic benefits in several distinc-
tive mouse models of glioma, the question of whether all human
GBMs will be similarly responsive remains open, recognizing
their heterogeneity and the diversity of driver mutations,
including rearrangements, and amplification of the EGFR and
PDGFR genes. Therefore, it will be important in future studies
to assess IM+TIC therapy alone and in combination with thera-
pies targeting distinct driver mutations in the broader genetic
landscape of glioma.
The experimental evidence congruently supports the interpre-
tation that IM+TIC accentuates autophagy by coordinately
elevating the level of cAMP. The importance of cAMP signaling
in gliomas has been highlighted in several studies. Thus,
CXCL12- or phosphodiesterase 4A1-mediated reduction in
cAMP levels in the brain promotes gliomagenesis following the
loss of NF1 (Warrington et al., 2007, 2010). Conversely, reactiva-
tion of cAMP signaling, or exposure of glioma cells to cAMP an-
alogs, inhibits growth of xenografted brain tumors or decreases
proliferation and survival of glioma cells in vitro (Goldhoff et al.,
2008; Hill et al., 2009; Sugimoto et al., 2013; Yang et al., 2007).
We now describe an alternative mechanism of increasing
cAMP levels in gliomas with a combination of FDA-approved
agents that elicit elevated rates of autophagy, with therapeutic
benefit. Our data suggest that although the PKA branch of the
cAMP signaling circuit is dispensable for this process, the
EPAC-branch mediates the cellular response to IM+TIC. Collec-
tively, our data indicate that IM+TIC increases cAMP levels in the
cell, which, via the EPAC branch of the cAMP signaling cascade,
induces AACD in glioma cells (Figure 7). Notably, we excluderolongs Survival of Mice with Brain Tumors
or-bearing GRLp53fko animals treated with vehicle (CTRL) or IM (40 mg/kg/
bars represent 10 mm. Graph shows the quantification of LC3 in tumors (puncta
using the unpaired Student’s t test.
ither vehicle control (CTRL) or treated with IM+TIC for 24 and 72 hr, determined
and LAMP1 co-localization as a percentage of total LAMP1 dots. ***p < 0.0001.
ntrol (I, II) or with IM+TIC for 24 hr (III, IV) or 48 hr (V–VIII). For organelle definition
nt 1 mm. IM+TIC-treated tumors show different stages of AACD (V–VIII), char-
Graph shows the quantitative analysis of tumor cells exhibiting the features of
. At least 22 independent images per section were analyzed. nd, not detected.
degradative AV; ER, endoplasmic reticulum; Lf, lipofuscin; Mi, mitochondrion.
a quantification of cellular organelles inGRLp53fko tumors, control and treated
isible nuclei were considered for each treatment. ns, no statistical significance.
r survival (right column) of s.c. xenografts from LN229 cells infected with shRNA
dpoint of 39 days, when control mice were at end stage (left). Survival was
pproximately 870 mm3 (right). ***p < 0.0001. ns, no statistical significance by a
average tumor volume of s.c. xenografts from LN229 cells described above,
70 mm3.
treatments initiated 24 hr after tumor detection (Supplemental Information).
est. The graph below shows the distribution of tumor grade (G) in end-stage
ents initiated 24 hr after tumor detection (Supplemental Information). *p < 0.02
istribution of tumor grade (G) in end-stage GRLp53fko animals is shown below.
imals following enrollment into trials. Data are represented as mean (±SEM).
nt’s t test.
incorporation (not shown) in the tumor samples from the cohorts analyzed in (I)
uantification of BrdU-positive cells is presented to the right. ns, no statistical
p<0.001 p<0.004
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Figure 6. Dual Treatment with IM+TIC Elevates cAMP Levels in Gliomas
(A) cAMP levels in tumor tissue adjusted to tumor weight. CTRL, vehicle-treated tumor-bearing animals; IM, TIC, and IM+TIC, tumor-bearing animals treated daily
for 3 days (Supplemental Information). At least three animals per condition were analyzed. The analysis was performed in triplicate. Statistical analysis used two-
way ANOVA.
(legend continued on next page)
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A B Figure 7. Schematic of the ProposedMech-
anismsUnderlying the Synergistic Effects of
IM+TIC on the Induction of AACD through
Elevated cAMP Signaling
(A) IM treatment activates adenylate cyclase and
induces cAMP-mediated autophagy. Autophagic
cells release ATP (Ayna et al., 2012). Extracellular
ATP is rapidly degraded into ADP and other ATP
metabolites. ATP and ADP can activate the
purinergic receptor P2Y12, triggering feedback
inhibition of adenylate cyclase activity, thereby
attenuating cAMP-mediated autophagy so as to
ameliorate excessive autophagy that can other-
wise result in AACD. Gsa, G protein subunit alpha.
(B) Combined exposure of cells to IM and the
P2Y12 inhibitor TIC short-circuits the ADP/ATP-
induced feedback inhibition of adenylate cyclase,
which increases cAMP levels, eliciting hyper-
activated autophagy and consequent cell death.
See also Figure S6.apoptosis and necroptosis as mediators of cell death in
response to these agents and functionally associate autophagy.
In contrast, TCAs have been shown to enhance apoptosis and
impair tumor growth in a mouse model of lung cancer (Jahchan
et al., 2013). Although autophagy was not assessed in this
study, the result suggests there may be context-dependent ef-
fects of TCAs in different tumors types, warranting further
investigation.
The role of autophagy in cancer progression is complex. The
outcome of autophagy activation in cancer cells depends on
the stage of the disease progression, cell type, oncogenic
drivers, and the intensity of the activating signal (White, 2012).
For example, in some instances, pharmacological induction of
autophagy can be cytoprotective, whereas subsequent inhibi-
tion of autophagy by lysosomotropic agents can result in
apoptosis (Fan et al., 2010). On the other hand, increasing evi-
dence suggests that some anticancer agents promote AACD
and that inhibition of autophagy under these conditions reduces
their cytotoxicity (for review, see Eberhart, 2014).
It is currently believed that AACD is the result of excessive
rates of autophagic flux this is distinct from death by apoptosis
or necroptosis (Marin˜o et al., 2014). Recently a panel of experts
in the field of cell death suggested the following criteria to define
AACD: (1) increased autophagic flux, (2) cell death without the
evident involvement of apoptosis, and (3) genetic inhibition of
autophagy by at least two regulatory factors suppresses the
cell killing (Galluzzi et al., 2012). The IM+TIC-mediated cell death
in vitro meets all the proposed requirements.(B) cAMP levels in human glioma cell lines LN71 and LN443, control or treated
concentration. The analysis was in triplicate and assessed by two-way ANOVA.
(C) A schematic representation of cAMP signaling cascade, illustrating where the
different branches of the cAMP pathway.
(D–F) Survival of LN71 cells treated for three days with vehicle, IM, or TIC alone, or
Me-cAMP-AC (F) in indicated concentrations. Statistical analysis was performed
(G) Representative immunoblotting analysis for EPAC1 protein expression in LN7
and sh228) or control shRNA (LO.1) cells. (Procedures are described in the Supp
(H) Survival of LN71 glioma cells, with or without knockdown of EPAC, subjected f
with the Cell Titer GloR (see Supplemental Information). *p < 0.0001 by two-way
(I) Survival of LN71 cells described and treated as in (G) and (H) analyzed by the
(J) Survival of LN71 cells described in (G), assessed by the LDH release method fo
See also Figure S5.
468 Cancer Cell 28, 456–471, October 12, 2015 ª2015 Elsevier Inc.The tumor-inhibiting role of autophagy in certain human can-
cers is increasingly being demonstrated (Aita et al., 1999). For
example, in GBM patients, comparatively higher levels of auto-
phagy are associated with better survival prognosis (Aoki et al.,
2008). Increased autophagic flux was recently shown to impair
tumor growth of NSCLC in mice (Xia et al., 2014), whereas inhi-
bition of autophagy by hydroxychloroquine accelerated tumor
formation in a model of pancreatic ductal adenocarcinoma
(Rosenfeldt et al., 2013). These results are all consistent with
the hypothesis that excessive autophagy can be tumor suppres-
sive. Our data add glioma to this growing list.
Aside from surgical removal, which is often not possible
because of tumor location and infiltration, the current conven-
tional therapy for glioma patients consists of ionizing irradiation
alone or in combination with the DNA alkalyting agent temozolo-
mide (Hegi et al., 2005; Stupp et al., 2005). Each of these thera-
pies elicits an increase in autophagic flux. A compelling body of
data obtained in vitro suggests that the observed autophagy is
enhancing therapeutic modalities by evoking AACD in cells
resistant to apoptosis (reviewed by Palumbo and Comincini,
2013). We now show that the use of agents that enhance
AACD reduces survival of glioma cells in vitro and restrains gli-
oma progression. It is reasonable to suggest that incorporation
of IM+TIC might enhance the therapeutic benefit of conventional
treatments for gliomas, and we are currently investigating this
possibility.
In summary, we describe the successful application of two
FDA-approved pharmacological agents to target glioma cellwith IM (40 mM), TIC (100 mM), or IM+TIC for 24 hr, adjusted to total protein
PKA inhibitor KT5720 and several cAMP analogs are proposed to act on the
in combination with cAMP analogs: dbcAMP (D), 8-CPT-cAMP (E), and 8-CPT-
by two-way ANOVA.
1 glioma cell lines infected with lentiviral vectors expressing shEPAC1 (sh231
lemental Information.)
or 3 days to treatment with 40 mM IM alone or in conjunction with TIC, analyzed
ANOVA.
trypan blue exclusion method. *p < 0.0001 by two-way ANOVA.
llowing exposure for 72 hr to IM and IM+TIC. *p < 0.0001 by two-way ANOVA.
survival and malignant progression by eliciting AACD via induc-
tion of the cAMP-signaling pathway. Notably, other analyzed in-
hibitors of the P2RY12 receptor, such as CDL or PGL, may prove
applicable to this mechanism-based therapeutic targeting, as
might other TCAs, affording flexibility in identifying combinations
with the best efficacy and toxicity profiles in humans.
The results presented herein offer a provocative strategy to
target apoptosis-resistant brain tumors by hyperactivating levels
of cellular autophagy; such dual targeting of autophagy with re-
purposed, pharmacologically tractable drugs may warrant
consideration for clinical trials.
EXPERIMENTAL PROCEDURES
Mouse Models and Bioluminescent Monitoring
Mice were housed, fed, and treated in accordance with protocols approved by
the committee for animal research of Canton Vaud, Switzerland. The de novo
and orthotopic models and manipulations are described in detail in Supple-
mental Experimental Procedures.
Luminescent images were obtained 5 min after injections of firefly D-lucif-
erin, potassium salt (L-8220; Biosynth) using an IVIS-100 Imaging System
(PerkinElmer) at field view D with the following parameters: 1 min exposure,
small binning, F/stop 1, emission filter open. The images were analyzed with
the Living Image 3.2 Analysis software package (Caliper, PerkinElmer). The
data were expressed as total photon flux (photons per second). Mice whose
tumor burden produced 3.5 3 106 to 4.5 3 106 photons per second in square
centimeters in regions of interest were enrolled into therapeutic trials (see Fig-
ures 1A, 1E, 5G, and 5H).
Immunoblotting, Histology and Immuno-histology, Cell Culture,
and Transmission EM
These procedureswere performed as described by Shchors et al. (2013) and in
the Supplemental Information.
cAMP Measurement
cAMP was measured by competitive immunoassay using the cAMP Direct
Immunoassay Kit (K371-100; BioVision) according to the manufacturer’s in-
structions, as described in the Supplemental Information.
Statistical Analysis and Quantification of Immune Staining
Data are presented as mean ± SEM from at least three independent experi-
ments, unless indicated otherwise. Kaplan-Meier survival curves were gener-
ated using GraphPad Prism 5. The statistical analysis of the survival curves
was done according to the Mantel-Cox test. The quantification of tumor prolif-
eration and apoptosis was performed using the Fiji software package (http://
rsb.info.nih.gov/ij).
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
six figures, and one table and can be found with this article online at http://
dx.doi.org/10.1016/j.ccell.2015.08.012.
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